Drug Trial Radar · NCT02961829
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure
Last checked: Nov 20, 2026Latest source record: Jul 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 2015
Primary completion
Mar 2019
Study completion Mar 2020
Sponsor
- Lead sponsor
- Federal University of São PauloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de Desenvolvimento Científico e Tecnológico; ViiV Healthcare
- First posted
- Nov 11, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is becoming clear that a combination of interventions will be desirable to achieve HIV cure. Therefore the investigators propose a pilot proof of concept study, using combination of a number of different interventions for eradicating residual plasma viremia and decreasing HIV reservoirs. The investigators hypothesize that, (i) antiretroviral intensification using Maraviroc, and/or dolutegravir with (ii) Dendritic Cell vaccination using autologous HIV, and (iii) purging intervention using the Class III HDACs, Sirtuin-1, and (iv) decreasing the ratio of long-lived central memory (TCM)/transitional memory (TTM) CD4+ T-cells using Auranofin will provide a synergistic impact leading to a sterilizing cure of HIV infection. Results of this study may provide insightful evidence for planning the next steps using the more efficacious combination of intervention strategies towards HIV sterilizing cure.
Conditions
- Chronic Infection
- HIV
Interventions
MaravirocDrug
antiretroviral intensification
DolutegravirDrug
antiretroviral intensification
Dendritic Cell VaccineBiological
Therapeutic vaccination
AuranofinDrug
purging
Sirtuin Histone deacetylase inhibitorDrug
latency disruption
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ultrasensitive RNA Viral load,Time frame: from baseline and every 4 weeks up to 48 weeks.
- Cell-associated HIV RNATime frame: from baseline and every 4 weeks up to 48 weeks.
- Episomal DNATime frame: from baseline and every 4 weeks up to 48 weeks
- specific HIV antibodiesTime frame: from baseline and every 4 weeks up to 48 weeks
- CD38 and HLA-DR on CD4 and CD8+ cellsTime frame: from baseline and every 4 weeks up to 48 weeks
- PBMC for env sequence evolutionTime frame: from baseline and every 4 weeks up to 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CCDI
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.